Publication | Open Access

Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer

NanoparticlesNanomedicineDrug TargetingEngineeringTherapeutic NanomaterialsMedicinePharmaceutical NanotechnologyNano-drug DeliveryOsimertinib-acquired ResistanceTumor TargetingPharmacologyRadiation OncologyLung Cancer